Journal of Vascular Surgery
Volume 45, Issue 6 , Pages 1142-1147 , June 2007

Aspirin resistance among long-term aspirin users after carotid endarterectomy and controls: Flow cytometric measurement of aspirin-induced platelet inhibition

  • Afshin Assadian, MD

      Affiliations

    • Department of General and Vascular Surgery, Wilhelminenspital Vienna, Vienna, Austria
    • Corresponding Author InformationReprint requests: Afshin Assadian, MD, Department of General and Vascular Surgery, Wilhelminenspital Vienna, Montleartstr 37, A-1160 Vienna, Austria.
    • ,
  • Jaqueline Lax, MS

      Affiliations

    • Department of Laboratory Medicine, Wilhelminenspital Vienna, Vienna, Austria.
    • ,
  • Ursula Meixner-Loicht, MD

      Affiliations

    • Department of General and Vascular Surgery, Wilhelminenspital Vienna, Vienna, Austria
    • ,
  • Georg W. Hagmüller, MD

      Affiliations

    • Department of General and Vascular Surgery, Wilhelminenspital Vienna, Vienna, Austria
    • ,
  • Peter Michael Bayer, MD

      Affiliations

    • Department of Laboratory Medicine, Wilhelminenspital Vienna, Vienna, Austria.
    • ,
  • Wolfgang Hübl, MD

      Affiliations

    • Department of Laboratory Medicine, Wilhelminenspital Vienna, Vienna, Austria.

Received 14 December 2006 ,Accepted 24 January 2007.

References 

  1. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest. 1975;56:624–632
  2. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975;72:3073–3076
  3. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:234S–264S
  4. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373–2383
  5. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006;367:606–617
  6. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost. 2003;1:1710–1713
  7. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost. 2005;3:1309–1311
  8. Szczeklik A, Musial J, Undas A, Sanak M, Nizankowski R. Aspirin resistance. Pharmacol Rep. 2005;57(suppl):33–41
  9. Payne DA, Jones CI, Hayes PD, Webster SE, Naylor AR, Goodall AH. Platelet inhibition by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance?. Thromb Haemost. 2004;92:89–96
  10. Webster SE, Payne DA, Jones CI, Hayes PD, Bell PRF, Goodall AH, et al. Anti-platelet effect of aspirin is substantially reduced after administration of heparin during carotid endarterectomy. J Vasc Surg. 2004;40:463–468
  11. Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient ischemic attack and stroke (Comparison of 2 point-of-care platelet function tests with optical aggregometry). Stroke. 2005;36:1001–1005
  12. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high grade stenosis. N Engl J Med. 1991;325:444–445
  13. Hillarp A, Lethagen S, Mattiasson I. Aspirin resistance is not a common biochemical phenotype explained by unblocked cyclooxygenase-1 activity. J Thromb Haemost. 2003;1:196–197
  14. Sambola A, Heras M, Escolar G, Lozano M, Pino M, Martorell T, et al. The PFA-100 detects sub-optimal antiplatelet responses in patients on aspirin. Platelets. 2004;15:439–446
  15. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke. 2004;35:175–178
  16. Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost. 2006;4:1271–1278
  17. Mitchell JA, Warmenr TD. Cox isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev. 2006;5:75–85
  18. Schmitz G, Rothe G, Ruf A, Barlage S, Tschope D, Clemetson KJ, et al. European Working Group on Clinical Cell Analysis: consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost. 1998;79:885–896
  19. Panzer S, Hocker L, Koren D. Agonists-induced platelet activation varies considerably in healthy male individuals: studies by flow cytometry. Ann Hematol. 2006;85:121–125
  20. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. MATCH investigators Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331–337
  21. Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, et al. CHARISMA Investigators Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. N Engl J Med. 2006;354:1706–1717
  22. Frelinger AL, Furman MI, Linden MD, Li Y, Fox ML, Barnar MR, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independant pathway (A 700-patient study of aspirin resistance). Circulation. 2006;113:2888–2896

 Competition of interest: none.

PII: S0741-5214(07)00229-7

doi: 10.1016/j.jvs.2007.01.064

Journal of Vascular Surgery
Volume 45, Issue 6 , Pages 1142-1147 , June 2007

Article Tools

* Image Usage & Resolution